Cuv is valued based on its cash balance and the fact that Scenesse will still be profitable for another two to three years. Then generics, competing products, etc. will come along. From the current perspective, Apart from their cash Clinuvel will no longer have any value after that. They can basically close the business down. I don't understand what your comparisons are supposed to achieve. You just have to look at Clinuvel on its own, and the valuation becomes clear.
CUV Price at posting:
$10.71 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)